Filing date | Form | Description | Filing Group | View |
---|---|---|---|---|
3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
3 | Initial filing by director officer or owner of more than ten percent. |
3,4,5
|
||
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
425 | Filing of certain prospectuses and communications in connection with business combination transactions |
Other
|
||
10-Q | Quarterly report which provides a continuing view of a company's financial position |
Quarterly Filings
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA | |
SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
SC 13D/A | An amendment to a SC 13D filing |
Other
|
||
8-K | Report of unscheduled material events or corporate event |
Current Reports
|
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA |
Data provided by Kaleidoscope.
GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.